Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX HELSINKI LTD.  >  Orion Oyj    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Orion Oyj : Prosecutor pressed charges against a member of Orion's Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

10/29/2020 | 12:00pm EST

ORION CORPORATION STOCK EXCHANGE RELEASE 29 OCTOBER 2020 at 19.00 EET             
         

Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

In accordance with the rules of the stock exchange, Orion Corporation discloses the following information:

It has come to the attention of Orion Corporation that Ari Lehtoranta, a member of Orion’s Board of Directors, has been charged in a securities markets case concerning suspected disclosure offence. According to the information Orion has, the matter is related to Mr. Lehtoranta’s operations as the CEO of Nokian Tyres Plc in 2015-2016. According to the information Orion has, Mr. Lehtoranta has denied any involvement in criminal activity.

The suspected offence is not related to Orion and Orion will not comment on the matter.

Orion Corporation

Timo Lappalainen
President and CEO
   Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                   
Contact person:
Terhi Ormio, VP, Communications
tel. +358 10 426 4646

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

 

© OMX, source OMX

All news about ORION OYJ
01/12ORION OYJ : Recommendation by the Nomination Committee concerning the Board of D..
AQ
2020NUVO PHARMACEUTICALS INC : . - Miravo Healthcare Ireland Enters into Suvexx Lice..
AQ
2020ORION OYJ : 8,242 Orion Corporation A shares converted into B shares
AQ
2020ORION OYJ : invests EUR 17 million in its production plants in Turku
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
AQ
2020Prosecutor pressed charges against a member of Orion's Board of Directors for..
GL
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
PU
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
AQ
2020Composition of the Nomination Committee of Orion Corporation
GL
More news
Financials
Sales 2020 1 090 M 1 316 M 1 316 M
Net income 2020 236 M 285 M 285 M
Net cash 2020 134 M 162 M 162 M
P/E ratio 2020 22,8x
Yield 2020 3,89%
Capitalization 5 497 M 6 647 M 6 641 M
EV / Sales 2020 4,92x
EV / Sales 2021 5,03x
Nbr of Employees 3 320
Free-Float 86,5%
Chart ORION OYJ
Duration : Period :
Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener
Technical analysis trends ORION OYJ
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 32,95 €
Last Close Price 38,18 €
Spread / Highest target 10,0%
Spread / Average Target -13,7%
Spread / Lowest Target -26,7%
EPS Revisions
Managers and Directors
NameTitle
Timo Antero Lappalainen President & Chief Executive Officer
Heikki Seppo Westerlund Chairman
Satu Maarit Ahomäki Senior Vice President-Commercial Operations
Jari Ilmari Karlson Chief Financial Officer & SVP-Animal Health
Sinikka Markkula Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
ORION OYJ1.73%6 506
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271